TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fusion Antibodies Plc ( (GB:FAB) ) has provided an announcement.
Fusion Antibodies plc reported a reduction in losses and increased R&D expenditure in its interim results for the first half of FY2026, despite a decrease in revenue compared to the previous year. The company highlighted significant progress with its OptiMAL® platform, including a successful validation project with the National Cancer Institute and the granting of a US patent. The commercial launch of OptiMAL® is on track, with positive feedback from prospective clients, indicating potential for a scalable licensing-based business model. Fusion Antibodies is well-positioned to capitalize on a recovering market and aims to expand its offerings to include additional libraries for diagnostics and veterinary medicine.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Underperform.
Fusion Antibodies Plc’s overall stock score is primarily driven by its challenging financial performance and weak technical indicators. The company’s negative profitability and cash flow issues are significant concerns, while the bearish technical signals suggest further downside risk. The valuation metrics also reflect the company’s financial difficulties, contributing to the low overall score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Contract Research Organisation based in Northern Ireland, specializing in antibody discovery, engineering, and expression services for human therapeutic, veterinary therapeutic, and diagnostic antibody development. The company offers a comprehensive range of services, including antibody discovery, development, characterization, optimization, and small-scale production, as well as antigen design and expression, antibody purification, and sequencing. Fusion Antibodies has a robust track record, having completed numerous humanization projects for top global pharmaceutical companies and is focused on speeding up drug discovery and development processes.
Average Trading Volume: 1,045,117
Technical Sentiment Signal: Buy
Current Market Cap: £13.64M
For detailed information about FAB stock, go to TipRanks’ Stock Analysis page.